How Much Does Pomalidomide Cost?

Patients with relapsed or refractory multiple myeloma often ask: How much does Pomalidomide cost, and what are my options if I can no longer afford treatment or if the medication stops working?

Pomalidomide is one of the most commonly used treatments for patients whose disease has progressed after earlier therapies. It remains an important part of modern myeloma care, but costs, availability, and reimbursement can vary significantly between countries.

For many patients, understanding the cost of Pomalidomide is also part of a larger question: what treatment options are available if multiple myeloma continues to progress?

Quick Overview: Pomalidomide Availability and Cost Considerations

Swipe table to see all columns

Country	Availability	Cost Considerations
United States	Available	Often covered by insurance, but patient responsibility varies
European Union	Available	Coverage depends on country and healthcare system
United Kingdom	Available under specific NHS criteria	May be covered for eligible patients
Israel	Available	Individual treatment quotation required
India	Available, including generic versions	Prices may be significantly lower than in Western countries
Other Countries	Varies	Availability and reimbursement depend on local regulations

Important: Pomalidomide pricing changes over time and varies by country, insurance coverage, and manufacturer. Patients should always obtain updated pricing information from their treating physician or pharmacy.

What Is Pomalidomide?

Pomalidomide is an oral medication used to treat multiple myeloma. It belongs to the same family of drugs as thalidomide and lenalidomide (Revlimid®) and works by helping the immune system attack myeloma cells while also interfering with cancer cell growth.

The medication is marketed under the brand name Pomalyst® in the United States and Imnovid® in many other countries.
Pomalidomide is usually taken at home and is commonly combined with dexamethasone and other myeloma therapies.

When Is Pomalidomide Used?

Pomalidomide is generally prescribed for patients whose disease has returned or progressed after previous treatment.
Many patients receiving Pomalidomide have already been treated with:

Lenalidomide (Revlimid)
Bortezomib (Velcade)
Daratumumab (Darzalex)
Stem cell transplant (bone marrow transplant)

It is considered an important treatment option for patients who have received multiple prior lines of therapy.

The cost of Pomalidomide varies dramatically around the world.
Several factors influence pricing:

Brand-name versus generic versions
Insurance coverage
National healthcare policies
Pharmaceutical regulations
Duration of treatment

In some countries, patients may pay thousands of dollars per month for treatment. In others, generic versions are available at substantially lower prices.

Because multiple myeloma treatment often continues for months or years, the total cost of therapy can become a significant concern for patients and families.

Why Are Prices Different Around the World?

One reason for the large differences in pricing is the availability of generic manufacturers.
The original drug was developed by Celgene, now part of Bristol Myers Squibb. However, generic versions are now manufactured in several countries.
As a result, patients may encounter significant differences in pricing depending on where treatment is obtained. For this reason, some international patients investigate treatment options outside their home country.

What Happens If Pomalidomide Stops Working?

Unfortunately, multiple myeloma often develops resistance to treatment over time.
While many patients benefit from Pomalidomide, some eventually experience disease progression despite treatment.
When this happens, physicians may consider:

CAR-T cell therapy
Bispecific antibodies such as Talquetamab or Teclistamab
Clinical trials
Additional combination therapies

The best option depends on the patient's previous treatments, overall health, and disease characteristics.

When Should Patients Consider CAR-T Therapy?

Many patients begin discussing CAR-T therapy after receiving several previous lines of treatment.
A typical treatment journey may include:

Initial therapy
Stem cell transplantation
Maintenance treatment
Lenalidomide (Revlimid)
Daratumumab-based combinations
Pomalidomide-based combinations
CAR-T therapy or bispecific antibodies

Not every patient follows the same path, but progression after treatments such as Pomalidomide often prompts physicians to evaluate newer options.
CAR-T therapy uses genetically modified immune cells designed to recognize and attack multiple myeloma cells. Unlike ongoing drug treatment, CAR-T is generally administered as a one-time cellular therapy.

For eligible patients, CAR-T therapy may produce deep and durable remissions, even after multiple previous treatments have failed.

Pomalidomide vs CAR-T Therapy

Pomalidomide and CAR-T therapy are not competing treatments. In many cases, patients receive both during different stages of their disease.

Swipe table to see all columns

Pomalidomide	CAR-T Therapy
Oral medication	Personalized cellular therapy
Taken continuously	Usually a one-time treatment
Commonly used in later treatment lines	Typically considered after multiple prior therapies
Available in many countries	Available at specialized treatment centers
May eventually lose effectiveness	Can produce deep responses in selected patients

Conclusion

Pomalidomide remains an important treatment option for patients with relapsed or refractory multiple myeloma.
For patients who have already received multiple prior lines of treatment, newer options such as CAR-T therapy and bispecific antibodies may offer additional opportunities for disease control.

Because every patient's situation is different, treatment decisions should be made in consultation with experienced myeloma specialists.

Sources